Use of Peptide-Based Inhibitors for Treating Pathogenic Bacterial Infection and Granulomatous Disease

Use of Peptide-Based Inhibitors of the STAT3-IL10 Pathway for Treating Pathogenic Bacterial Infection and Granulomatous Disease

Opportunity

Available for Licensing

IP Status

US Utility Patent: US 10512673

Inventors

Mercedes Gonzalez-Juarrero
Nadya I. Tarasova

Unaltered Image (Left): Chest x-ray showing dense homogenous opacity in right, middle and lower lobe of primary pulmonary TB. Courtesy of (2018). “The Radiological Diagnosis of Pulmonary Tuberculosis (TB) in Primary Care”. Journal of Family Medicine and Disease Prevention 4 (1). DOI:10.23937/2469-5793/1510073. ISSN 24695793. (Image Link)

At A Glance

Researchers at Colorado State University in collaboration with the Department of Health and Human Services have developed and patented a novel treatment of patients infected with pathogenic bacterial infection or granulomatous disease using peptide-based inhibitors reducing persistent infection by more than 90%.

Licensing Manager

Jessy McGowan
Jessy.McGowan@colostate.edu
970-491-7100

Reference No.: 15-066

Background

Current chemotherapy for tuberculosis (TB) fails to eliminate rapidly the Mycobacterium tuberculosis bacilli and to control TB globally. Treatment for drug susceptible TB today requires 6-9 months of multidrug therapy. As for TB patients with multi-drug resistant (MDR) – TB infections, treatment is endured for two years and is unsuccessful in more than 50% of the cases. To improve TB control globally, shorter, effective, and well-tolerated treatments for latent TB infection is desired as this is the only way to reduce the development of resistance against the new chemical entities.

Technology Overview

The treatment encompasses a novel utility for IL-10 and STAT3 peptide inhibitors. Data from animal models demonstrated that both STAT3 N-domain and IL-10R peptide inhibitors significantly reduced the persistent infecting Mycobacterium tuberculosis (Mtb) bacilli load in the lungs and modulated the lung host immune response to enhance its own bactericidal capacity infected with Mtb.

Applications

Commercially valuable therapeutic approach for targeting persistent infecting Mycobacterium tuberculosis (Mtb) bacilli in the lungs
TB therapy in combination with current standard chemotherapies

Publications

Upadhyay, Rashmi, et al. “Host Directed Therapy for Chronic Tuberculosis via Intrapulmonary Delivery of Aerosolized Peptide Inhibitors Targeting the IL-10-STAT3 Pathway.” Scientific Reports, Nature Publishing Group UK, 9 Nov. 2018, www.ncbi.nlm.nih.gov/pmc/articles/PMC6226451/.

Last updated: February 2020

Add keywords or various names of inventors here (text is hidden)

#CSUInvents – #TechTuesday! Current #chemotherapy for #tuberculosis (TB) fails to rapidly eliminate the Mycobacterium tuberculosis bacilli. To improve #TB control globally, shorter, effective, and well-tolerated treatments for latent TB infection is desired as this is the only way to reduce #resistance to treatment. Researchers at Colorado State University in collaboration with the U.S. Department of Health and Human Services (HHS) and The National Institutes of Health, National Cancer Institute (NCI) have developed and #patented a #novel treatment for patients infected with #pathogenic bacterial infection or #granulomatous disease using #peptide-based #inhibitors reducing persistent infection by more than 90%. This technology is also posted at the NIH Center for Information Technology.

Inventors include: Mercedes Gonzalez Juarrero #CSU and Nadaya I. Tarasova #NIH #NCI.

#innovation

https://lnkd.in/eiVWpdF